Related Experiment Video
Updated: Feb 16, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Modernizing Human Cancer Risk Assessment of Therapeutics
Mark R Fielden1, Lucas D Ward1, Sheroy Minocherhomji1
1Amgen, One Amgen Center Drive, Thousand Oaks, CA, USA.
Abstract:
Cancer risk assessment of therapeutics is plagued by poor translatability of rodent models of carcinogenesis. In order to overcome this fundamental limitation, new approaches are needed that enable us to evaluate cancer risk directly in humans and human-based cellular models. Our enhanced understanding of the mechanisms of carcinogenesis and the influence of human genome sequence variation on cancer risk motivates us to re-evaluate how we assess the carcinogenic risk of therapeutics. This review will highlight new opportunities for applying this knowledge to the development of a battery of human-based in vitro models and biomarkers for assessing cancer risk of novel therapeutics.
Insights
Traditional rodent models for cancer risk assessment in therapeutics show poor translatability. New human-based models and biomarkers are needed to accurately evaluate therapeutic cancer risk.
Area of Science:
- Oncology
- Toxicology
- Genetics
Background:
- Rodent models for evaluating therapeutic cancer risk have limitations in translatability to human outcomes.
- Understanding cancer mechanisms and human genetic variations is crucial for accurate risk assessment.
Purpose of the Study:
- To review and highlight new approaches for assessing the carcinogenic risk of therapeutics.
- To explore the development of human-based in vitro models and biomarkers for cancer risk evaluation.
Main Methods:
- Review of current literature on carcinogenesis and therapeutic risk assessment.
- Discussion of advancements in understanding human genome variation's role in cancer.
- Exploration of novel human-based in vitro models and biomarker strategies.
Main Results:
- Identified limitations in current rodent-based cancer risk assessment models.
- Highlighted the importance of human-specific data and models.
- Proposed a shift towards human-based in vitro systems and biomarkers.
Conclusions:
- New human-based in vitro models and biomarkers offer improved accuracy for therapeutic cancer risk assessment.
- Integrating knowledge of carcinogenesis mechanisms and human genetics is key.
- This approach promises more reliable evaluation of novel therapeutics' safety.
More Related Videos
09:20Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
Published on: June 26, 2018
05:39Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine
Published on: April 5, 2024
Related Concept Videos
Mutagenicity and Carcinogenicity
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Targeted Cancer Therapies
There are several types of targeted therapies against...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...